Loading…
Urinary collagen type II C-telopeptide fragments are sensitive markers of matrix metalloproteinase-dependent cartilage degradation in rat adjuvant-induced arthritis
OBJECTIVE: To assess the relevance of collagen type II C-telopeptide fragments (CTX-II) as markers of cartilage degradation during adjuvant-induced arthritis in rats. METHODS: Rats were injected with Freund's adjuvant on day 0 and treated orally for 21 days twice a day with vehicle or 10 or 20...
Saved in:
Published in: | Journal of rheumatology 2003-07, Vol.30 (7), p.1561-1564 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | OBJECTIVE: To assess the relevance of collagen type II C-telopeptide fragments (CTX-II) as markers of cartilage degradation
during adjuvant-induced arthritis in rats. METHODS: Rats were injected with Freund's adjuvant on day 0 and treated orally
for 21 days twice a day with vehicle or 10 or 20 mg/kg of a newly designed matrix metalloproteinase inhibitor (MMP-Inh). Urine
samples were collected for 24 h between days 19 and 20 and the concentration of the cartilage-derived CTX-II was measured
with a 2-site, sandwich-type ELISA. To assess arthritis, inflammatory scores were determined, and changes in paw volumes were
measured by plethysmography. RESULTS: On day 21, the inflammation was generalized in rats injected with Freund's adjuvant.
The urinary concentration of CTX-II was significantly higher in arthritic rats than in control non-injected rats. Oral treatment
of arthritic rats with MMP-Inh dramatically decreased the concentration of CTX-II in urine, with values returning to those
of controls. Treatment simultaneously reduced the clinical variables of the disease. CONCLUSION: These results demonstrate
that fragments of type II collagen in urine can be used as a measure of cartilage degradation in arthritic rats as well as
potent non-invasive markers of the efficacy of chondroprotective treatments. |
---|---|
ISSN: | 0315-162X 1499-2752 |